Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
9.48 USD | +0.96% | +1.39% | +100.42% |
Strengths
- The prospective high growth for the next fiscal years is among the main assets of the company
- Upward revisions of sales forecast reflect a renewed optimism among the analysts covering the stock.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
- The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.
Weaknesses
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Sector: Drug Retailers
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+100.42% | 673M | - | ||
+18.36% | 2.94B | D+ | ||
+13.95% | 1.68B | - | ||
+3.41% | 482M | - | ||
+49.77% | 188M | - | ||
+2.77% | 110M | - | ||
+1.67% | 96.49M | - | - | |
+42.70% | 53.89M | - | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
- Stock Market
- Equities
- GLASF Stock
- Ratings Glass House Brands Inc.